Aurora Cannabis (NYSE:ACB) versus Tauriga Sciences (NYSE:TAUG) Head-To-Head Review

Aurora Cannabis (NYSE:ACB) and Tauriga Sciences (OTCMKTS:TAUG) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.


This table compares Aurora Cannabis and Tauriga Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aurora Cannabis -122.65% 1.24% 1.05%
Tauriga Sciences N/A -282.02% -134.76%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Aurora Cannabis and Tauriga Sciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis 0 4 5 0 2.56
Tauriga Sciences 0 0 0 0 N/A

Aurora Cannabis currently has a consensus price target of $8.72, indicating a potential upside of 30.89%. Given Aurora Cannabis’ higher possible upside, equities research analysts plainly believe Aurora Cannabis is more favorable than Tauriga Sciences.

Valuation and Earnings

This table compares Aurora Cannabis and Tauriga Sciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aurora Cannabis $43.49 million 155.30 $56.66 million $0.12 55.50
Tauriga Sciences $60,000.00 51.05 -$1.10 million N/A N/A

Aurora Cannabis has higher revenue and earnings than Tauriga Sciences.

Institutional & Insider Ownership

9.0% of Aurora Cannabis shares are owned by institutional investors. 6.2% of Tauriga Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Aurora Cannabis has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500. Comparatively, Tauriga Sciences has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.


Aurora Cannabis beats Tauriga Sciences on 9 of the 11 factors compared between the two stocks.

Aurora Cannabis Company Profile

Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company's products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. As of February 26, 2019, the company had operations in 24 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies. The company has a strategic agreements with Hempco Food and Fiber Inc.; CTT Pharmaceuticals Inc.; Choom Holdings Inc.; Capcium Inc.; The Green Organic Dutchman Holdings Ltd.; Société des Alcools du Québec; Alcanna; Radient Technologies; Micron Waste; Wagner Dimas; Evio; and Cann Group Limited. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Tauriga Sciences Company Profile

Tauriga Sciences, Inc. produces, licenses, and sells lip balm products under the HerMan brand name. The company was founded in 2001 and is based in New York, New York.

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with's FREE daily email newsletter.